William J. Garner, MD MPH
Dr. William (Bill) Garner is a physician, investor and entrepreneur. Through EGB Ventures, Dr. Garner has made numerous public and private investments. Bill is currently Chairman of Race Oncology (ASX:RAC). Race Oncology is based on patents filed by EGB. Bill is Chairman of InMed Pharmaceuticals, Inc. (CSE:IN).

Dr. Garner co-founded DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI). At Delmar, Bill introduced the other co-founders, served on the board, and facilitated DelMar’s listing in 2013.

In 2012, Dr. Garner merged Inverseon, Inc. with another company to form Invion Ltd. (ASX:IVX), serving as CEO until May of 2013. The Inverseon pulmonary therapeutic is Phase 3 ready, having completed four positive clinical trials.

Dr. Garner also served as President and Chief Executive Officer of Urigen Pharmaceuticals, Inc. from December 2005 to December 2010 where he moved a procedure-based drug from a university license to a phase II multi-center clinical trial that achieved statistical significance on all end points in Painful Bladder Syndrome/Interstitial Cystitis. Over 10,000 patients have benefited from the therapy on a compassionate basis in three countries to date.

Previously, Dr. Garner worked in medical affairs at Hoffmann LaRoche in oncology. Prior to Roche, Dr. Garner was a merchant banker in New York City.

Dr. Garner has a Master of Public Health from Harvard and received his M.D. degree from New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York.

Among awards and honors, Dr. Garner was an AMA/Glaxo Wellcome Leadership Award recipient. Some of Dr. Garner’s research was funded by the American Federation for Aging Research.